Biopharmaceuticals (includes Biologics)

Cannabinoids: Therapeutic Applications and Regulatory Pathways

Session Leader(s)

• 

  Judith Plon, MBA, RAC

  Vice President, Regulatory Affairs

Speaker(s)

• 

  Karen Long, MSc, RAC

  Sr. Director, Drug Development
• 

  Jessica O'Connell, JD, MPH

  JD, MPH

One year after the approval of Epidiolex (cannabidiol), cannabinoid-based products are on everyone’s radar. From the shops across New York City or seen on Instagram selling cannabidiol (CBD) food, beverages, dietary supplements, and cosmetics, to the multiple cannabinoid drugs under development worldwide, interest in cannabinoids, hemp, and marijuana has traversed all health industries. This session will give an overview of the regulatory and legal status of cannabinoids for use in drugs and food, in the US and Canada. The aim of the session is to give participants a better understanding of the relevant definitions (i.e. hemp vs. marijuana) and the latest laws regulating the ability to research and develop cannabinoid-based health products. It will also help identify the key challenges and uncertainties each industry faces, with perspective from industry members currently working on such products.

Learning Objectives:

• Learn about the current and growing landscape of CBD products
• Gain a better understanding of the relevant definitions (i.e. hemp vs. marijuana) and the latest laws regulating the ability to research and develop cannabinoid-based health products
• Identify the key challenges and uncertainties each industry faces while developing these products, with perspective from industry members currently working on such products